Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy

2024-9-1

Jeffrey S Weber, MD, PhD (1952–2024): in memoriam to discovery, friendship and family

2024-9-1

scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC

2024-9-1

Intratumoral CXCL13⁺CD160⁺CD8⁺T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer

2024-9-1

Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study

2024-9-1

Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8⁺T cell infiltration

2024-9-1

Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy

2024-9-1

Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma

2024-9-1

Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models

2024-9-1

Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade

2024-9-1

MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers

2024-9-1

Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway

2024-9-1

Targeting<i>Gsk3a</i>reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma

2024-8-1

Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study

2024-8-1

Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy

2024-8-1

Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy

2024-8-1

Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8⁺T cells and inhibited tumor growth

2024-8-1

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

2024-8-1

S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling

2024-8-1

Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC

2024-8-1

Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer

2024-8-1

Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity

2024-8-1

Immune checkpoint blockade: timing is everything

2024-8-1

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment

2024-8-1

NKG2C/<i>KLRC2</i>tumor cell expression enhances immunotherapeutic efficacy against glioblastoma

2024-8-1

Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy

2024-8-1

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

2024-8-1

An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade

2024-8-1

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus

2024-8-1

NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors

2024-8-1

Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells

2024-8-1

Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study

2024-8-1

Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer

2024-8-1

Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018–2022

2024-8-1

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

2024-8-1

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

2024-8-1

Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors

2024-8-1

Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer

2024-8-1

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

2024-8-1

ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages

2024-8-1

EphA3 CAR T cells are effective against glioblastoma in preclinical models

2024-8-1

Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies

2024-7-1

Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy

2024-7-1

Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species

2024-7-1

IFNγ mediates the resistance of tumor cells to distinct NK cell subsets

2024-7-1

Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma

2024-7-1

Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?

2024-7-1

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

2024-7-1

Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

2024-7-1

Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma

2024-7-1